期刊文献+

帕金森病患者骨质疏松的临床观察 被引量:5

Clinical observation of osteoporosis in Parkinson’s disease patients
下载PDF
导出
摘要 目的探索帕金森病(Parkinson’s disease,PD)患者发生骨质疏松症的危险因素及其与PD非运动症状的关系。方法对58例PD患者和63例健康查体人群进行研究,其中PD伴骨质疏松25例,PD不伴骨质疏松33例。检测所有受试者腰椎及一侧股骨颈骨密度(BMD)和血清25-羟维生素D(25OHD)水平,收集PD患者年龄、性别、体质量指数、左旋多巴等效日剂量(LED)、血清同型半胱氨酸(Hcy)水平,并对其进行国际运动障碍协会统一帕金森病评定量表Ⅲ部分(MDS-UPDRSⅢ)、Hoehn-Yahr分期(H-Y分期)评测及情绪、认知、睡眠等非运动症状进行评分。结果PD组股骨颈BMD、腰椎总BMD、25OHD均低于对照组,骨质疏松率、25OHD缺乏率均高于对照组(均P值<0.05)。女性、左旋多巴等效日剂量、高同型半胱氨酸血症、H-Y分期晚期、低体质指数是PD发生骨质疏松的危险因素。情绪、认知、睡眠等非运动症状与PD患者骨质疏松不相关。结论PD患者是发生骨质疏松的高危人群,应针对其发生骨质疏松的相关危险因素采取干预措施,降低致残、致死率。 Objective The purpose of this study is to explore the risk factors of osteoporosis in patients with Parkinson's disease(PD)and the relationship between osteoporosis and non-motor symptoms of PD.Methods 58 PD patients and 63 healthy people were studied,including 25 cases of PD with osteoporosis and 33 cases of PD without osteoporosis.The bone mineral density(BMD)and serum 25-hydroxyvitamin D(25OHD)levels of lumbar vertebrae and femoral neck of all subjects were detected.The age,sex,body mass index,levodopa equivalent daily dose(LED)and serum homocysteine(Hcy)levels of PD patients were collected,and they were evaluated by the International Association for Motor Disorders Unified Parkinson’s Disease Rating Scale Ⅲ(MDS-UPDRS Ⅲ),Hoehn-Yahr Stage(H-Y Stage)and scored for non-motor symptoms such as emotion,cognition and sleep.Results In PD group,BMD of femoral neck,total BMD of lumbar spine and 25OHD were lower than those in control group,while osteoporosis rate and 25OHD deficiency rate were higher than those in control group(P<0.05).Female,equivalent daily dose of levodopa,hyperhomocysteinemia,late H-Y stage and low body mass index are the risk factors of osteoporosis in PD.Emotion,cognition,sleep and other non-motor symptoms are not related to osteoporosis in PD patients.Conclusion PD patients are a high-risk group with osteoporosis.Intervention measures should be taken to reduce the disability and mortality rate according to the related risk factors of osteoporosis.
作者 马速 顾平 仇福成 董慈 王文婷 韩瑞 刘少娜 王欣 MA Su;GU Ping;QIU Fucheng;DONG Ci;WANG Wenting;HAN Rui;LIU Shaona;WANG Xin(Department of Neurology, First Hospital of Hebei Medical University, Brain Aging and Cognitive Neuroscience Laboratory of Hebei Province, Shijiazhuang 050011, China)
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2021年第6期838-842,共5页 Chinese Journal of Osteoporosis
基金 河北省重点科技研究计划(ZD20140308)。
关键词 帕金森病 骨密度 骨质疏松 25-羟维生素D Parkinson’s disease bone mineral density osteoporosis 25-hydroxyvitamin D
  • 相关文献

参考文献9

二级参考文献87

  • 1杨帆,徐妙容,杨妙馥,林志恒,刘满堂,袁志辉.中药治疗骨质疏松症的用药规律(英文)[J].中国临床康复,2005,9(31):203-205. 被引量:6
  • 2王刚,郑汭,谭玉燕,孙小康,周海燕,叶晓来,王瑛,王增,孙伯民,陈生弟.帕金森病疾病经济负担及相关因素的调查研究[J].中华神经科杂志,2006,39(5):336-337. 被引量:26
  • 3王锡娟,梁日欣,赵璐,高伟.中药复方骨疏康防治骨质疏松症研究进展[J].中国中西医结合杂志,2007,27(3):282-285. 被引量:11
  • 4Invernizzi M,Carda S,Viscontini GS,et al.Osteoporosis in Park-inson's disease[J].Parkinsonism Relat Disord,2009,15(5):339-346.
  • 5Sato Y, Honda Y, Iwamoto J,et al.Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients[J].Mov Disord,2005,20(12):1598-1603.
  • 6Daniel SK,Lansang MC,Okun MS.Bone mineral density (BMD)in male patients with Parkinson's disease[J].Int J Neurosci,2012 [Epub ahead of print].
  • 7Suzan Abou-Raya,Madihah Helrnii,Anna Abou-Raya.Bone and mineral metabolism in older adults with Parkinson's disease[J]. Age Ageing,2009,38(6):675 -678.
  • 8de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol, 2006, 5:525-535.
  • 9Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J Neurol, 2008, 255 (Suppl 5):18-32.
  • 10Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol, 2002, 55:25-31.

共引文献766

同被引文献38

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部